The Pattern of Progression to First-Line Treatment with Dabrafenib and Trametinib in Patients with Unresectable or Metastatic, BRAF-Mutated, Cutaneous Melanoma: Results of the Observational T-WIN Study

The Pattern of Progression to First-Line Treatment with Dabrafenib and Trametinib in Patients with Unresectable or Metastatic, BRAF-Mutated, Cutaneous Melanoma: Results of the Observational T-WIN Study

In patients with B-RAF-mutated cutaneous melanoma, targeted therapies are the treatment of choice to achieve a rapid response. In this multicentric, prospective, observational study, patients with B-RAF-mutated cutaneous melanoma who were treated with dabrafenib and trametinib were categorized in tw...

Full description

Bibliographic Details
Main Authors: Michele Del Vecchio, Vanna Chiarion Sileni, Pietro Quaglino, Gaetana Rinaldi, Alessandro Minisini, Teresa Troiani, Francesca Consoli, Andrea Sponghini, Maria Banzi, Maria Francesca Morelli, Dario Palleschi, Ernesto Rossi, Riccardo Marconcini, Roberta Depenni, Fabrizio Carnevale-Schianca, Ilaria Marcon, Paola Queirolo
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:Cancers
Subjects:
metastatic melanoma
unresectable melanoma
dabrafenib
trametinib
lactate dehydrogenase
BRAF V600 mutation
Online Access:https://www.mdpi.com/2072-6694/15/7/1980

Internet

https://www.mdpi.com/2072-6694/15/7/1980

Similar Items